Understanding Tobacco And Tobacco Harm Reduction: A Path Forward
Developing and commercializing reduced risk tobacco products has been one of PMI’s top priorities for many years. Underlying the development of these products is the need for scientific validation of the risk reduction potential of such products. PMI would like to share with you how Toxicology and Systems Biology are helping the company meet this significant challenge. During the symposium, PMI scientists will present their research on Toxicology and Systems Biology approaches.
Schedule
1 July
M Smith
Review Of Smoke Chemistry Methodology And Reduction Of Selected Harmful And Potentially Harmful Constituents (HPHCs) In Mainstream Smoke
1 July
1 July
S Boue
Systems Toxicology In ApoE-/- Mice Demonstrates Similar Benefits Of Switch To pMRTP And Smoking Cessation For Both Cardiovascular And Lung Disease-Related Endpoints
1 July
U Kogel
28-Day Rat Inhalation Study – How Systems Toxicology Complements OECD Inhalation Studies
1 July
B Phillips
A Mechanistic Study Of Cigarette Smoke-Induced COPD And Cessation Effects In C57bl/6 Mice
1 July
C Mathis
Systems Toxicology Assessment Of The Effect Of Repeated Cigarette Smoke Exposure On Human Respiratory Tract Tissue Cultures
1 July
A Iskandar
Systems Toxicology Approaches Enable Mechanistic Comparison Of Cigarette Smoke-Induced And Spontaneous Lung Tumors In The A/J Mouse Model
1 July
I Gonzalez-Suarez
In Vitro Evaluation Of The Biological Impact Of Harmful And Potentially Harmful Constituents Of Tobacco Smoke Using A Systems Toxicology Approach
1 July
E Bilal
Crowd-Verification Of Systems Biology Research Challenges: Species Translation And Biological Networks
1 July
B Phillips
Systems Toxicology-Based Comparisons Of Smoking Cessation And Switching To A Non- Combustible Tobacco Product In A Murine Model Of COPD
